Loading...
Cidara Therapeutics, Inc.
CDTX•NASDAQ
Healthcare
Biotechnology
$61.85
$-0.97(-1.54%)
Cidara Therapeutics, Inc. (CDTX) AI-Powered Stock Analysis
See how Cidara Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCidara Therapeutics, Inc. (CDTX) Stock Overall Grade
Cidara Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
B
Good
Grade Breakdown by Metric
See how each financial and market factor contributes to Cidara Therapeutics, Inc.'s overall stock rating.
Forecast
BScore
68/100Financial Growth
CScore
45/100Fundamental Growth
CScore
41/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
B+Score
75/100Cidara Therapeutics, Inc. (CDTX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 68/100 (B), reflecting high confidence in its potential. Financial Growth (45/100, C) and Fundamental Growth (41/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Cidara Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.